Trial Profile
A randomized, double-blinded, placebo-controlled trial to assess the antidepressant effects of the NMDA antagonist, CP-101 606 [traxoprodil], in patients with treatment refractory major depressive disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2009
Price :
$35
*
At a glance
- Drugs Traxoprodil (Primary) ; Paroxetine
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- 01 Dec 2008 Results were published in the Journal of Clinical Psychopharmacology.
- 02 Nov 2005 New trial record.